The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | The role of glasdegib in AML
Nicholas Short, MD, University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses the role of glasdegib in acute myeloid leukemia (AML), which was approved by the FDA for older patients unfit for intensive chemotherapy. Despite the approval of this agent, Dr Short explains that the combination of azacitidine and venetoclax explored in the VIALE-A trial (NCT02993523) demonstrated better response rates in patients, and is therefore more commonly used than combinations with glasdegib. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
